These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10612710)

  • 1. Synergistic interactions of endogenous opioids and cannabinoid systems.
    Welch SP; Eads M
    Brain Res; 1999 Nov; 848(1-2):183-90. PubMed ID: 10612710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
    Houser SJ; Eads M; Embrey JP; Welch SP
    Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing CB1 receptor GIRK channel responses to receptor internalization using a kinetic imaging assay.
    Andersen HK; Vardakas DG; Lamothe JA; Perault TEA; Walsh KB; Laprairie RB
    Sci Rep; 2024 Aug; 14(1):18314. PubMed ID: 39112591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
    Mason DJ; Lowe J; Welch SP
    Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
    Pugh G; Mason DJ; Combs V; Welch SP
    J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
    Solinas M; Goldberg SR
    Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interactions between cannabinoid and opioid analgesics.
    Cichewicz DL
    Life Sci; 2004 Jan; 74(11):1317-24. PubMed ID: 14706563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioids and cannabinoids interactions: involvement in pain management.
    Desroches J; Beaulieu P
    Curr Drug Targets; 2010 Apr; 11(4):462-73. PubMed ID: 20017728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of the cannabinoid and opioid systems in the modulation of nociception.
    Welch SP
    Int Rev Psychiatry; 2009 Apr; 21(2):143-51. PubMed ID: 19367508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP; Huffman JW; Lowe J
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors.
    Lake KD; Compton DR; Varga K; Martin BR; Kunos G
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1030-7. PubMed ID: 9190833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of endocannabinoid receptor agonist anandamide and antagonist rimonabant on opioid analgesia and tolerance in rats.
    Altun A; Ozdemir E; Yildirim K; Gursoy S; Durmus N; Bagcivan I
    Gen Physiol Biophys; 2015 Oct; 34(4):433-40. PubMed ID: 26374993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
    Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
    Haller VL; Stevens DL; Welch SP
    Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception.
    Williams J; Haller VL; Stevens DL; Welch SP
    Eur J Pharmacol; 2008 Apr; 584(1):78-86. PubMed ID: 18313663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
    Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
    Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.
    Karst M; Wippermann S
    Expert Opin Investig Drugs; 2009 Feb; 18(2):125-33. PubMed ID: 19236260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta.
    O'Sullivan SE; Kendall DA; Randall MD
    Eur J Pharmacol; 2005 Jan; 507(1-3):211-21. PubMed ID: 15659311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH; Sheikh SM; Loh HH; Martin BR
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.